FCGR3A and neoplasm: From a therapeutic point of view, our results strongly support the use of bispecific antibodies as a dual targeting strategy, both neutralizing EGFR on tumor cells and recruiting FcγRIIIa+ TAN in contact with tumor cells to boost the ADCC-mediated tumor cell lysis.